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ABSTRACT 18 
Prion diseases are a unique group of transmissible, typically sub-acute, neurodegenerative 19 
disorders.  During CNS prion disease the microglia become activated and are considered to 20 
provide a protective response by scavenging and clearing prions.  The mammalian intestine is 21 
host to a large burden of commensal microorganisms, especially bacteria, termed the 22 
microbiota.  The commensal microbiota exerts many beneficial effects on host health including 23 
the metabolism of essential nutrients, regulation of host development, and protection against 24 
pathogens.  The commensal gut microbiota also constitutively regulates the functional 25 
maturation of microglia in the CNS, and microglial function is impaired in its absence in 26 
germfree mice.  In the current study we determined whether the absence of the commensal gut 27 
microbiota might also affect prion disease pathogenesis.  Our data clearly show that the 28 
absence of the commensal microbiota in germfree mice did not affect prion disease duration 29 
or susceptibility after exposure to prions by intraperitoneal or intracerebral injection.  30 
Furthermore, the magnitude and distribution of the characteristic neuropathological hallmarks 31 
of terminal prion disease in the CNS, including the development of spongiform pathology, 32 
accumulation of prion disease-specific PrP, astrogliosis and microglial activation, were similar 33 
in conventionally-housed and germfree mice.  Thus although the commensal gut microbiota 34 
constitutively promotes the maintenance of the microglia in the CNS under steady-state 35 
conditions in naïve mice, our data suggest that dramatic changes to the abundance or 36 
complexity of the commensal gut microbiota are unlikely to influence CNS prion disease 37 
pathogenesis.   38 
 39 
Key words:  prions; transmissible spongiform encephalopathies; microbiota; brain; central 40 
nervous system, CNS; microglia. 41 
 42 
Abbreviations: BSE, bovine spongiform encephalopathy; CNS, central nervous system; d, 43 
days; FDC, follicular dendritic cell; GALT, gut-associated lymphoid tissues; GFAP, glial 44 
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fibrillary acidic protein; IC, intracerebral; IHC, immunohistochemistry; ILF, isolated 45 
lymphoid follicle; IP, intraperitoneal; PrP, prion protein; SCFA, short chain fatty acid; SPF, 46 
specific pathogen free; vCJD, variant Creutzfeldt-Jakob disease.   47 
48 
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INTRODUCTION 49 
Prion diseases, or transmissible spongiform encephalopathies, are typically sub-acute 50 
neurodegenerative diseases which affect humans and a number of captive and free-ranging 51 
animal species.  During prion diseases affected tissues are characteristically associated with 52 
abundant aggregations of PrPSc, abnormally folded isoforms of the host-encoded cellular prion 53 
protein, PrPC [1].  Cumulative scientific evidence suggests that PrPSc is the major, if not sole, 54 
component of the infectious prion agent [2, 3].  Once the prions establish infection in the CNS 55 
they often cause extensive neuropathology which is typically characterised by the activation 56 
of microglia and astrocytes, accumulations of PrPSc and neurodegeneration [4, 5].   57 
Microglia are the tissue macrophages of the CNS and play important roles in 58 
maintaining neuronal homeostasis, synaptic remodelling, clearing dead and dying cells and 59 
providing a first line of defence against pathogens [6-9].  A change in microglial status, from 60 
resting to activated, is amongst the first pathological features observed during CNS prion 61 
disease, occurring before the onset of neuropathology [4, 10].  Within the prion disease-62 
affected brain an anti-inflammatory cytokine milieu appears to be induced in order to stimulate 63 
the microglia to protect the host by scavenging and clearing prions and prion-affected cells 64 
[11-15].   However, systemic administration of inflammatory stimuli such as bacterial LPS 65 
during CNS prion disease can switch the microglial phenotype to one with a more pro-66 
inflammatory bias, leading to exacerbated neuropathology [16, 17].  Consistent with this 67 
hypothesis, prion disease is delayed in mice deficient in CD14 (a component of the LPS 68 
receptor) and is accompanied by enhanced expression of anti-inflammatory cytokines such as 69 
IL-10 [18].   70 
The mammalian gastrointestinal tract is home to a vast community of commensal 71 
microorganisms, termed the microbiota [19].  For example, the large intestine of the adult 72 
human may contain approximately 100 trillion microorganisms, and represent over 1000 73 
different bacterial species.  The commensal gut microbiota provides a diverse range of 74 
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beneficial effects on host health including the metabolism of essential nutrients [20], 75 
influencing the development and regulation of the immune system [21, 22] and providing 76 
protection against pathogens by outcompeting them for nutrients or habitats [23].   77 
A bidirectional neurohumoral communication system, termed the gut-brain axis, can 78 
integrate neural, hormonal and immunological signalling between these two tissues.  This 79 
enables the brain to influence a variety of physiological activities in the intestine including 80 
motility and secretion, and the actions of the mucosal immune system [24].  Gut- and 81 
microbiota-derived products can also influence the brain, for example, through the release of 82 
cytokines or hormones from enteroendocrine cells, or via stimulation of afferent neural 83 
pathways of the vagus nerve and spinal cord.  These in-turn can influence the composition of 84 
the gut microbiota, either directly, or due to physiological effects on the intestine (for reviews 85 
see [24-27]).  Exciting data have revealed that the commensal gut microbiota constitutively 86 
maintains the homeostasis of the microglia in the brains of naïve mice under steady-state 87 
conditions [28].  Furthermore, the functional maturation of the microglia was compromised in 88 
germfree mice and coincided with their significantly reduced responses to LPS-stimulation or 89 
virus infection in the CNS [28].  The nature of the microglial activation status during CNS 90 
prion disease is considered to influence the severity of the neurodegeneration [5], but whether 91 
the commensal gut microbiota also influenced prion disease pathogenesis was uncertain [29].  92 
Modifications to the gut microbiota can contribute to the pathogenesis of anxiety and 93 
depression, and certain neurodegenerative disorders such as Alzheimer’s disease and 94 
Parkinson’s disease [30].  Therefore, in the current study, prion disease pathogenesis and 95 
susceptibility were compared in conventional and germfree mice to determine whether 96 
significant reductions to the abundance of the commensal gut microbiota might also affect 97 
prion disease pathogenesis and susceptibility.   98 
 99 
 100 
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RESULTS 101 
Groups of conventionally-housed mice (SPF control) and germfree mice were injected with 102 
prions by either the IC (n=10/group) or IP (n=9/group) routes and survival times and disease 103 
incidence compared.  As anticipated, all the conventionally-housed mice succumbed to clinical 104 
prion disease with a mean survival time of 174 ± 2 days (d) after IC exposure (median 175 d), 105 
and 248 ± 3 d after IP exposure (median 247 d; Table 1).  Our data show that the 106 
microbiological status of the mice did not significantly affect survival times or disease 107 
susceptibility as all the germfree mice succumbed to clinical disease with similar survival 108 
times when injected with prions by either of these exposure routes (IC, mean 174 ± 0 d, median 109 
175 d, P = 0.702; IP, mean 245 ± 3 d, median 245 d, P = 0.576).  These data clearly demonstrate 110 
that the absence of the commensal microbiota in germfree mice does not influence disease 111 
susceptibility or duration when infected with prions directly into the CNS (IC) or after 112 
peripheral exposure via the peritoneal cavity (IP). 113 
 During prion diseases aggregations of prion disease-specific PrP (PrPd) accumulate in 114 
affected tissues.  IHC analysis suggested that the abundance of prion disease-specific PrPd 115 
within the brains of the clinically-affected conventionally-housed or germfree mice was 116 
similar (Fig. 1).  Prion infection within the CNS also leads to the development of significant 117 
spongiform pathology (vacuolation) in the neuropil (Fig. 2A).  We therefore compared the 118 
magnitude of the spongiform pathology within nine distinct grey matter regions in the brains 119 
of all the clinically-affected mice from each group.  Irrespective of the microbiological status 120 
of the mice, the average severity and distribution of the spongiform pathology within the brains 121 
of the clinically-affected mice after IC or IP injection with prions was similar (Fig. 2B and C, 122 
respectively).  These data clearly show that the absence of the commensal microbiota in 123 
germfree mice did not affect the accumulation of PrPd in the brain or the development of 124 
spongiform pathology at the clinical stage of disease.   125 
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Microglial activation is another prominent histopathological feature within the prion 126 
disease-affected brain [4, 5, 10].  Since the commensal microbiota can constitutively regulate 127 
the functional maturation of the microglia [28], we next compared the status of the microglia 128 
in the brains of conventionally-housed and germfree mice with clinical prion disease.  Our 129 
IHC analysis suggested a similar abundance of Iba1+ microglia in the brains of the clinically-130 
affected conventionally-housed and germfree mice after IC or IP injection with prions (Fig. 131 
3A).  Morphometric analysis of nine distinct grey matter regions also indicated equivalent 132 
areas of Iba1+ immunostaining in the brains of mice from each group (Fig. 3B, IC-injected; 133 
Fig. 3C, IP-injected).   134 
Independent histopathological analyses have demonstrated increased microglial size 135 
and densities in the brains of naïve germfree mice [28].  A similar semi-automatic quantitative 136 
morphometric analysis approach was used here to compare the density and morphology of the 137 
Iba1+ microglia in the brains of conventionally-housed and germfree mice with clinical prion 138 
disease.  From each group, six individual mice were sampled, and from each of their brains, 139 
data were collected from at least 25 individual Iba1+ microglia within the dorsal medulla (G1) 140 
and hippocampus (G6) regions.  Our data clearly show that the density and morphology of the 141 
microglia within each region was similar in brains from clinically-affected conventionally-142 
housed or germfree mice (Fig. 4).  No significant differences between groups were observed 143 
in the number of microglia within regions, or in the length of dendrites, number of segments, 144 
branching points or terminal points on individual microglia (Fig. 4B).   Thus although the 145 
commensal gut microbiota may control the homeostasis of the microglia under steady-state 146 
conditions in naïve mice [28], our data show that its absence does not significantly affect the 147 
density or morphology of microglia during CNS prion disease.   148 
CNS prion disease is also accompanied by the induction of reactive astrocytes 149 
expressing high levels of GFAP.  Our IHC analysis showed that the abundance of GFAP+ 150 
immunostaining across nine distinct grey matter regions was similar in the brains of 151 
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conventionally-housed or germfree mice at the terminal stage of prion disease (Fig. 5).  These 152 
data are consistent with the independent demonstration that the number of GFAP+ astrocytes 153 
in the brain was not affected by the absence of the commensal microbiota in naïve germfree 154 
mice [28].   155 
 156 
 157 
DISCUSSION 158 
The commensal gut microbiota can constitutively regulate the functional maturation of the 159 
microglia in the CNS, and influence their responses to LPS-stimulation or CNS virus infection 160 
[28].  Disturbances to the gut microbiota can contribute to the pathogenesis of several human 161 
neurodegenerative diseases [30].  Microglial activation is a prominent feature of CNS prion 162 
disease [4, 10], but whether the commensal gut microbiota influenced the progression of CNS 163 
disease was uncertain [29, 31, 32].  Data in the current study clearly demonstrate that prion 164 
disease pathogenesis and susceptibility after exposure by either the IP or IC routes is not 165 
influenced by the absence of the commensal gut microbiota in germfree mice.  We also show 166 
that the microbiological status of the host did not influence the magnitude or distribution of 167 
the characteristic neuropathological hallmarks of terminal prion disease in the CNS, including 168 
the development of spongiform pathology, accumulation of disease-specific PrP, astrogliosis 169 
and microgliosis.  Thus, these data suggest that dramatic changes to the abundance or 170 
complexity of the commensal gut microbiota are unlikely to influence prion disease duration 171 
or susceptibility, or the development of neuropathology in the CNS.  Of course, our data cannot 172 
exclude the possibility that an effect of the microbiota on CNS disease pathogenesis may have 173 
been observed after exposure of the germ free mice to a much lower dose of prions than used 174 
in the current study.   175 
Data presented in the current study appear to contradict data reported in two 176 
independent studies reported more than 20 years ago [31, 32].  However, fundamental 177 
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differences in experimental design and purpose make direct comparisons between these studies 178 
difficult.  In an attempt to define the nature of the scrapie prion agent, Lev and colleagues 179 
infected conventionally-housed and germfree CD1 mice with lyophylized and irradiated 180 
preparations of the Chandler mouse-adapted scrapie isolate by the IC route.  Survival times 181 
were reported to be extended in the germfree mice, but from data presented it is uncertain 182 
whether this effect was significant [31].  In a later study, Wade and colleagues compared prion 183 
disease survival times after IC or IP injection with ME7 scrapie prions in germfree mice, with 184 
those colonized with a highly restricted Gram-positive bacterial microflora [32].  Consistent 185 
with data presented in the current study, survival times after IC prion exposure were not 186 
influenced by the microbiological status of the mice, but a prolongation was observed in the 187 
germfree mice after IP exposure [32].  Precise explanations for the inconsistencies between 188 
data in this study and the current study are uncertain, but a highly restricted Gram-positive 189 
bacterial microflora similar to that used as a control in the Wade study can itself influence 190 
microglial status [28].  After IP exposure to prions the early accumulation and replication of 191 
the prions upon follicular dendritic cells (FDC) within the B cell follicles of the spleen is 192 
essential for them to subsequently infect the CNS, termed neuroinvasion [33-35].  Certain 193 
bacterial constituents of the commensal gut microbiota can have a profound influence on the 194 
function and development of the host immune system [22, 36, 37].  Therefore, the possibility 195 
cannot be excluded that a highly restricted Gram-positive bacterial flora may have enhanced 196 
prion neuroinvasion from the spleen after IP exposure, shortening the survival times when 197 
compared to germfree mice.    198 
The study by Erny and colleagues [28] showed that the pro-inflammatory responses of 199 
microglia after LPS stimulation were diminished in the brains of germfree mice.  The 200 
microglial phenotype during CNS prion disease, in contrast, is considered to be predominantly 201 
anti-inflammatory to enable the microglia to protect the host by scavenging and clearing prions 202 
[11-15].  In the current study our data show that microglial abundance and complexity in the 203 
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brains of mice with clinical prion disease were unaltered in the absence of the microbiota.  204 
Effects of the microbiota on the microglial response to anti-inflammatory stimuli were not 205 
determined in the above study [28].  However, it is plausible that the influence of the 206 
microbiota on microglia may be dependent on their activation status and phenotype.   207 
Many of the actions of the commensal microbiota on the host immune system have 208 
been shown to be mediated through the ability of some bacterial species to break down 209 
indigestible dietary fibre into short chain fatty acids (SCFA) [22].  Furthermore, microglial 210 
development can be restored in germfree mice by the administration of SCFA [28].  The human 211 
“Western diet” is characteristically high in fat and simple carbohydrates, and can modify the 212 
constituents of the commensal gut microbiota by decreasing the abundance of Bacteroidetes 213 
which are important providers of SCFA [38, 39].  Despite the potential to induce significant 214 
changes to the commensal gut microbiota, CNS prion pathogenesis is not significantly affected 215 
in mice raised on a high-fat diet [40].   216 
The replication of certain prion strains upon FDC in the gut-associated lymphoid 217 
tissues (GALT) in the small intestine (such as the Peyer’s patches and isolated lymphoid 218 
follicles, ILF) is essential for efficient neuroinvasion after oral exposure [41-45].  Although 219 
data in the current study suggest that dramatic changes to the abundance or complexity of the 220 
commensal gut microbiota do not influence CNS prion disease pathogenesis or susceptibility 221 
after IC or IP exposure, potential effects on susceptibility to orally-acquired prion infections 222 
cannot be excluded.  Cross-talk between the host immune system and the commensal 223 
microbiota can significantly influence the development and function of the GALT [36, 37, 46].  224 
Mature ILF, comprising individual B cell-follicles with a network of FDC can act as important 225 
sites of prion accumulation and neuroinvasion in the small intestine [43, 44].  The density of 226 
ILF is reduced in the small intestines of germfree mice [46], implying that microbiota-227 
mediated alterations to GALT abundance or status in the small intestine could significantly 228 
affect oral prion disease susceptibility by influencing the uptake, replication and neuroinvasion 229 
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of prions from the gut lumen.  Further studies are clearly necessary to study the effects of the 230 
commensal gut microbiota on oral prion disease susceptibility.  However, the use of germfree 231 
mice is not appropriate here as these mice have altered gastrointestinal motility and transit time 232 
[47] and substantially enlarged caeca [48], which could have profound effects on the uptake 233 
of prions from the gut lumen after oral exposure.   234 
Although changes to the abundance or complexity of the commensal gut microbiota 235 
are unlikely to influence prion disease duration or susceptibility, concurrent gastrointestinal 236 
infection with pathogenic bacteria or systemic exposure to their pro-inflammatory components 237 
can exacerbate prion disease pathogenesis.  For example, systemic treatment with bacterial 238 
LPS can induce an aggressive pro-inflammatory phenotype in the microglia in the prion 239 
disease-affected brain, leading to increased neuropathology and accelerated disease 240 
progression [49, 50].  Pathology to the gut epithelium at the time of oral prion exposure, such 241 
as that caused by oral infection with the enteroinvasive bacterium Salmonella Typhimurium,  242 
can also increase prion disease susceptibility [51], most likely through the enhanced uptake of 243 
prions from the gut lumen [52].   244 
Despite the apparent widespread exposure of the UK human population to bovine 245 
spongiform encephalopathy (BSE) prions through the food chain [53, 54], relatively low 246 
numbers of clinical cases of variant Creutzfeldt-Jakob disease (vCJD) in humans have 247 
fortunately been reported [55].  However, data from the retrospective analyses of PrPSc 248 
accumulation in archived human GALT specimens suggest the prevalence of vCJD infection 249 
may be higher than the clinical cases suggest [56].  This implies the potential existence of a 250 
subclinical carrier state.  A thorough understanding of the factors which influence the 251 
progression of the preclinical phase will help to identify those which enhance the risk of 252 
developing clinical prion disease.  For example, the presence of prion-specific PrPSc within 253 
specific regions of the brains of prion-affected hosts is insufficient on its own to trigger 254 
neurodegeneration [5].  Neurodegeneration was observed to occur only when PrPSc 255 
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accumulation was associated with an upregulated innate immune response by the microglia 256 
within the same brain regions.  This indicates that factors which manipulate the activation 257 
status of the microglial may have a significant impact on the magnitude of the 258 
neurodegeneration exhibited during CNS prion disease.  For example, factors which enhance 259 
clearance of prions by microglia may reduce disease pathogenesis.  Conversely, factors which 260 
enhance the destruction of neurones by microglia may enhance the progression of CNS prion 261 
disease [49, 50].  However, although the commensal gut microbiota can control the functional 262 
maturation of microglia, data presented in the current study suggest that dramatic changes to 263 
the commensal microbiota are unlikely to influence the development of CNS prion disease.   264 
 265 
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METHODS 288 
Mice 289 
C3H/LacDk mice (6-10 wk old) were used throughout this study.  Where indicated, some mice 290 
were conventionally-housed and maintained under standard specific pathogen free (SPF) 291 
conditions.  Others were bred and maintained under strict germfree conditions in sterile 292 
isolators.  SPF mice and germ free mice were each housed in groups of 4-6 in conventional 293 
cages with sterilized aspen chip bedding, under a 12 hour light/12 hour dark cycle, and 294 
provided with unrestricted access to sterile water and food (RM1, Special Diet Services, Essex, 295 
UK).  The germfree status of the colony was continually maintained over many years and 296 
confirmed by the regular microbial testing of sentinel mice from the same isolators.  Indeed, 297 
in separate studies our analyses confirmed that germfree mice from our colony had the 298 
disturbed development of gut-associated lymphoid tissues in their intestines and substantially 299 
enlarged caeca [46] reported in independent studies of germfree mice elsewhere [48, 57, 58].  300 
All studies and regulatory licences were approved by Neuropathogenesis Unit’s ethics 301 
committee and carried out under the authority of a UK Home Office Project Licence.   302 
 303 
Prion exposure and disease monitoring 304 
Where indicated mice were injected by either the intracerebral (IC) or intraperitoneal (IP) 305 
routes with 20 µl of a 1.0 % (w/v) dilution of scrapie brain homogenate prepared from mice 306 
terminally-affected with 22C scrapie prions (containing approximately 4.5 log IC infectious 307 
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dose50 units).  The brains used to prepare the homogenate used in this study were washed in 308 
absolute alcohol and -irradiated before use to eliminate potential contamination from 309 
commensal microorganisms.  Following prion exposure, mice were coded and assessed 310 
weekly for signs of clinical disease and culled at a standard clinical endpoint.  The clinical 311 
endpoint of disease was determined by rating the severity of the clinical signs of prion disease 312 
exhibited by the mice.  Mice were clinically scored as “unaffected”, “possibly affected” and 313 
“definitely affected” according to the standard clinical characteristics which are typically 314 
present in mice with terminal scrapie prion disease.  Clinical signs following infection of mice 315 
with scrapie prions may include: weight-loss, ruffled or starry/spikey fur, hunched posture, 316 
jumpy behaviour (at early onset) progressing to limited movement, upright tail, wet genitals, 317 
decreased awareness, discharge from eyes/blinking eyes, ataxia of hind legs.  The clinical 318 
endpoint of disease was defined in one of the following ways: i) the day on which a mouse 319 
received a second consecutive “definite” rating; ii) the day on which a mouse received a third 320 
“definite” rating within four consecutive weeks; iii) the day on which a mouse was culled in 321 
extremis.  Survival times were recorded for mice that did not develop clinical signs of disease 322 
during the observation period.  Prion diagnosis was confirmed by histopathological assessment 323 
of vacuolation in the brain.  For the construction of lesion profiles, vacuolar changes were 324 
scored in nine distinct grey-matter regions of the brain as described [59].   325 
 326 
Immunohistochemisty (IHC) 327 
For the detection of prion disease-specific PrP (PrPd), brains were fixed in paraformaldehyde 328 
fixative and embedded in paraffin wax.  Sections (thickness, 6 µm) were deparaffinised, and 329 
pre-treated to enhance the detection of PrPd by hydrated autoclaving (15 minutes, 121ºC, 330 
hydration) and subsequent immersion in formic acid (98%) for 5 minutes.  Sections were then 331 
immunostained with PrP-specific mAb BH1 [60].  For the detection of astrocytes, brain 332 
sections were immunostained with anti-glial fibrillary acidic protein (GFAP; DAKO, Ely, 333 
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UK).  For the detection of microglia, deparaffinised brain sections were first pre-treated with 334 
citrate buffer and subsequently immunostained with anti-ionized calcium-binding adaptor 335 
molecule 1 (Iba1; Wako Chemicals GmbH, Neuss, Germany).  Following the addition of 336 
primary antibodies, biotin-conjugated species-specific secondary antibodies (Stratech, Soham, 337 
UK) were applied and immunolabelling was revealed using HRP-conjugated to the avidin-338 
biotin complex (ABC kit, Vector Laboratories, Peterborough, UK) and visualized with DAB 339 
(Sigma).  Sections were counterstained with haematoxylin to distinguish cell nuclei.    340 
 341 
Image analysis 342 
For morphometric analysis, images were analysed using ImageJ software 343 
(http://rsb.info.nih.gov/ij/) as described on coded sections [61].  Background intensity 344 
thresholds were first applied using an ImageJ macro which measures pixel intensity across all 345 
immunostained and non-stained areas of the images.  The obtained pixel intensity threshold 346 
value was then applied in all subsequent analyses.  Next, the number of pixels of each colour 347 
were automatically counted.  For these analyses, data are presented as the proportion of 348 
positively-stained pixels for a given IHC marker per total number of pixels (all colours) in the 349 
specific area of interest.  In each instance tissues from six mice/group were analysed.  Details 350 
of all the sample sizes for each parameter analysed are provided in the figure legends.   351 
The density and morphology of Iba1+ microglia was analysed using Imaris 8.2.1 352 
software (Bitplane, Belfast, UK) according to a previously established protocol [28].  From 353 
each mouse group six individual mice were sampled, and from each of these mice data were 354 
collected from at least 25 individual Iba1+ microglia within the dorsal medulla (G1) and 355 
hippocampus (G6) regions of their brains.  Microglial morphology was compared by 356 
measuring dendrite length, numbers of segments, branching and terminal points.  Thus, from 357 
each mouse group data were collected from at least 150 individual Iba1+ microglia.   358 
 359 
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Statistical analyses 360 
Unless indicated otherwise, data are presented as mean ± SE and significant differences 361 
between groups were sought by Student’s t-test.  Values of P < 0.05 were accepted as 362 
significant.   363 
364 
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Fig. 1.  Influence of the commensal gut microbiota on the distribution of prion disease-specific 525 
PrP within the brains of mice with terminal prion disease.  Conventionally-housed or germfree 526 
mice were injected with 22C prions by the IC or IP routes, and brains collected at the terminal 527 
stage of disease.  Sections were immunostained to detect PrP (brown) and counterstained with 528 
haematoxylin (blue) to detect cell nuclei.  This IHC analysis suggested that the absence of the 529 
commensal gut microbiota in germfree mice did not influence the distribution of disease-530 
specific PrP within the brain.  Representative images are presented from 6 mice/group.  Scale 531 
bar, 100 µm. 532 
 533 
Fig. 2.  The commensal gut microbiota does not influence the magnitude or distribution of the 534 
spongiform pathology within the brain at the terminal stage of prion disease.  Conventionally-535 
housed or germfree mice were injected with prions by the IC (n=10/group) or IP (n=9/group) 536 
routes, and brains collected at the terminal stage of disease.  A)  High levels of spongiform 537 
pathology were detected in the brains of all the conventionally-housed and germfree mice with 538 
terminal prion disease.  Sections were stained with haematoxylin and eosin.  Scale bar, 100 539 
µm.  Mice were infected with prions by the IC (B) or IP (C) routes, and at the terminal stage 540 
of the disease the severity and distribution of the spongiform pathology (vacuolation) within 541 
each brain was scored on a scale of 1–5 in nine grey matter areas: G1, dorsal medulla; G2, 542 
cerebellar cortex; G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; 543 
G7, septum; G8, retrosplenial and adjacent motor cortex; G9, cingulate and adjacent motor 544 
cortex.  Each point represents the mean vacuolation score ± SE.  IC (n=10/group) or IP 545 
(n=9/group).     546 
 547 
Fig. 3.  Influence of the commensal gut microbiota on the distribution of microglia within the 548 
brains of mice with terminal prion disease.  Conventionally-housed or germfree mice were 549 
injected with prions by the IC or IP routes and brains collected at the terminal stage of disease.  550 
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A) Sections were immunostained to detect microglia (Iba1+ cells, brown) and counterstained 551 
with haematoxylin (blue) to detect cell nuclei.  Scale bar, 100 µm.  Morphometric analysis 552 
revealed that the area of the Iba1+ immunostaining in nine distinct grey matter regions (regions 553 
as in the legend to Fig. 2) was similar in the brains of clinically-affected conventionally-housed 554 
and germfree mice infected with prions by the IC (B) or IP (C) routes.  n = 6 mice/group.   555 
 556 
Fig. 4. Semi-automatic quantitative morphometric analysis of the density and morphology of 557 
microglia in the brains of conventionally-housed or germfree mice with terminal prion disease.  558 
A) Representative Imaris-based reconstructions of Iba1+ microglia in the hippocampus region 559 
of mice from each group.  B) Imaris-based quantitative cell morphometry of Iba1+ microglia 560 
in the dorsal medulla (left-hand panels) and hippocampus (right-hand panels) regions.   From 561 
each mouse group, six individual mice were sampled, and from each of their brains, data were 562 
collected from at least 25 individual Iba1+ microglia within each brain region.  Solid bars, 563 
conventionally-housed mice; open bars, germfree mice.  No significant differences between 564 
groups were observed in the number of microglia within regions, or in the length of dendrites, 565 
number of segments, branching points or terminal points on individual microglia.   566 
 567 
Fig. 5.  Influence of the commensal gut microbiota on the distribution of reactive astrocytes 568 
within the brains of mice with terminal prion disease.  Conventionally-housed or germfree 569 
mice were injected with prions by the IC or IP routes, and brains collected at the terminal stage 570 
of disease.  A) Sections were immunostained to detect astrocytes (GFAP+ cells, brown) and 571 
counterstained with haematoxylin (blue) to detect cell nuclei.  Scale bar, 100 µm.  572 
Morphometric analysis revealed that the area of the GFAP+ immunostaining in nine distinct 573 
grey matter regions (regions as in the legend to Fig. 2) was similar in the brains of clinically-574 
affected conventionally-housed and germfree mice infected with prions by the IC (B) or IP (C) 575 
routes.  n = 6 mice/group.   576 
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 577 
 578 
Table 1.  Prion disease susceptibility in conventional and germfree mice 579 
 580 
 
 
 
 
 
Group 
 
 
 
Route of 
prion 
exposure* 
 
 
Individual 
survival 
times 
(days) 
 
Mean 
survival 
times 
(days ± 
SE)  
 
 
 
 
Clinical 
disease† 
 
 
 
Vacuolar 
pathology 
in brain 
 
 
 
 
P 
value‡ 
       
Conventional  IC 163, 168, 
2X 173, 
5X 175, 
185 
174 ± 2 10/10 
 
10/10  
       
Germfree IC 3X 173, 
7X 175 
174 ± 0 10/10 
 
10/10 0.702 
 
Conventional  
 
IP 
 
2X 238, 
2X 245, 
249, 252, 
255, 257, 
261 
 
248 ± 3 
 
9/9 
 
 
9/9 
 
 
 
 
Germfree 
 
IP 
 
235,  
2X 236, 
3X 245, 
248, 258, 
261 
 
245 ± 3 
 
9/9 
 
 
9/9 
 
 
0.576 
       
 581 
* Mice were injected IC or IP with 20 µl of a 1.0% dose of mouse-passaged 22C 582 
scrapie prions. 583 
† Incidence = no. animals affected/no. animals tested.   584 
‡ Conventional vs. germfree, Student’s t-test.   585 
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